Left ventricular diastolic function is the ability of the left ventricle to relax and then fill under normal chamber pressures, which is an important part of a normal cardiac cycle. When left ventricular diastolic function is altered, usually by impaired left ventricular relaxation and increased left ventricular chamber stiffness, left ventricular filling develops under high pressures and left ventricular diastolic dysfunction (LVDD) is established.
Left ventricular diastolic function is the ability of the left ventricle to relax and then fill under normal chamber pressures, which is an important part of a normal cardiac cycle. When left ventricular diastolic function is altered, usually by impaired left ventricular relaxation and increased left ventricular chamber stiffness, left ventricular filling develops under high pressures and left ventricular diastolic dysfunction (LVDD) is established. 1 In the general population, asymptomatic LVDD has a prevalence above 25%, rising up to 64% in high-risk subjects. 2, 3 Furthermore, even in preclinical stages, LVDD is associated with an increased risk of incident heart failure and both fatal and non-fatal cardiovascular events. 2, 4 Thus because of its high prevalence and adverse-related outcomes, LVDD is an important public health problem and prevention target.
Echocardiographic assessment of left ventricular function is an important tool for clinical evaluation that is performed through several parameters because no variable alone is diagnostic of LVDD. Among common parameters are: early transmitral flow velocity (E), late transmitral flow velocity (A), early mitral annulus velocity (e 0 ), tricuspid regurgitation systolic jet velocity (TR) and left atrial maximum volume index, among others. According to current recommendations, LVDD is present if more than half of the suggested variables (E/e 0 , e 0 , TR and left atrial volume index) meet the cut-off values. 1 However, echocardiographic definitions and cut-off values have some particular concerns in subclinical LVDD: many individuals are classified as having 'indeterminate' left ventricular diastolic function and there is a lower LVDD prevalence in population studies, 3, 5 criteria based largely on expert consensus reports 1 and technical limitations (e.g. high operator dependence) among others.
Biomarkers of left ventricular diastolic function and dysfunction
The natural history and pathophysiology of LVDD has attributed a potential role for biomarkers in the prevention, diagnosis and management of LVDD in its early stages. 2, 6 Although a large amount of evidence is available about biomarkers in heart failure with preserved and reduced ejection fraction, there is a large unfilled research gap in LVDD, especially in the early or asymptomatic phases. The FLEMENGHO study -a landmark family-based population study from Belgium -has helped to fill this research gap by relating different biomarkers with echocardiographic parameters of high diastolic pressure.
Over the past decade FLEMENGHO's researchers have reported different blood and urinary biomarkers of left ventricular diastolic function and LVDD, which are summarised in Table 1 . The FLEMENGHO study has associated left ventricular function (assessed mainly as E, A, e 0 and E/e 0 ) and LVDD with genetic polymorphism, urinary proteomics, circulating markers of collagen turnover, markers of cardiomyocyte injury, cytokines and circulating metabolites related to energy substrate utilisation and oxidative stress protection. A few other studies have identified different biomarkers of LVDD: natriuretic peptides, long non-coding RNAs, markers of collagen turnover, pentaxine-3, thiol, fatty acid-binding protein 4 (FAB4), inflammatory markers and peroxisome proliferator-activated receptor polymorphisms (see Table 1 ).
Natriuretic peptides (such as brain natriuretic peptide (BNP) and NT-proBNP) have been researched mostly for the diagnosis of heart failure with preserved ejection fraction, 6 conditions in which LVDD is usually present. However, some studies have researched natriuretic peptides in asymptomatic LVDD (Table 1) . In addition to FLEMENGHO, the Horn Study and other studies performed in the general population have reported higher BNP and proBNP levels in subjects with LVDD, and an inverse relationship with echocardiographic measures of left ventricular function, with a higher strength of association in diabetes, in which basal BNP levels also predict left ventricular diastolic function at follow-up. 7 Moreover, in individuals with cardiovascular risk factors, plasma levels of NT-proBNP and high-sensitivity cardiac troponin T could indicate subclinical organ damage and cognitive impairment. 8, 9 Finally, the STOP-HF trial in high-risk patients proved that BNP-based screening and collaborative care reduce the prevalence of asymptomatic left ventricular dysfunction, with or without heart failure, but not the prevalence of asymptomatic LVDD alone after adjusting for baseline characteristics. 10 To our knowledge, no other biomarker has proved its utility regarding the treatment or prevention of LVDD.
Circulating metabolites as biomarkers of diastolic function
In the current issue of the European Journal of Preventive Cardiology, FLEMENGHO's researchers used a non-targeted metabolomic approach to associate circulating metabolites with left ventricular diastolic function and predict asymptomatic LVDD at a 5-year follow-up. 11 A total of 570 participants from the community were enrolled to asses left ventricular diastolic function by echocardiography (e 0 , E/e 0 and E/A) and to measure 43 circulating metabolites by nuclear magnetic resonance spectroscopy. Cross-sectional analysis indicated that higher valine and glucose plus taurine values were associated with greater e 0 , while higher valine and 2-oxobutyrate values were inversely associated with E/e 0 . In a longitudinal analysis, higher pantoate at baseline was associated with lower e 0 , and higher valine and glucose plus taurine at baseline were associated with lower E/e 0 at follow-up. After adjustment for baseline characteristics, the risk of LVDD or LVDD progression incidence at follow-up decreased with higher baseline glucose plus taurine. Through pathway analysis, the most important pathways associated with LVDD included branched chain amino acid metabolism and aminoacyl-tRNA.
The results described above are important to advance in filling the research gap regarding LVDD biomarkers. First of all, most of the community-based studies -including those about natriuretic peptidesare cross-sectional studies with known methodical limitations; however, the present study longitudinally relates circulating biomarkers with left ventricular diastolic function. And second, there is biological plausibility to propose branched chain amino acids as biomarkers, based on their catabolic pathway in LVDD. Thus a new potential circulating biomarker for early stages of LVDD is born.
Current limitations and high pressure need for research
Despite the strengths of the article of Zhang and collaborators, 11 some limitations need to be addressed by answering the following questions. What were the mean and standard deviation of the main metabolites that were studied? Do circulating metabolites have a considerable biological variability? What frequent conditions or comorbidities affect their values? Is the strength of 
Conclusion
In summary, even though the presented article represents an important advance in the field of LVVD, many issues remain unsolved regarding the utility of circulating metabolic biomarkers of left ventricular diastolic function. However, the paper presents a new biomarker to address in research and also recalls the importance of filling the research gap under 'high pressure' for better cardiovascular health.
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